News and Trends 11 Jan 2023 Lifesciences and biotech in 2023 A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging year—at least financially—in biotech. Do you see those trends continuing? Although we see overall sentiments to invest in biotech turning positive in 2023 after a […] January 11, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 2023 Editorial Calendar updated Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special editions are an opportunity to take a deeper look at topics of interest. It also allows us to focus on some of the special awareness days – of which there are many – associated with health and the life sciences. […] January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Watch: Norway’s Pre Diagnostics looks to early detection of Alzheimer’s Pre Diagnostics AS is a new Norwegian company developing and commercializing an innovative and effective diagnostic test for Alzheimer’s disease (AD). Founded by an experienced biotech team, Pre Diagnostics owns the licensed rights to a patent-protected new diagnostic test from the Norwegian university hospital AHUS. The company said it will pursue cost-efficient product development with […] December 22, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 ‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward A huge step forward in dementia research has been hailed a truly historic moment by researchers working to find a cure for people with Alzheimer’s Disease. This is the first time a drug being trialed, lecanemab, has shown a reduction in the disease in the brain while slowing memory decline. Dr Susan Kohlhaas, director of […] November 30, 2022 - 6 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […] November 30, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 23 Nov 2022 What recent mixed clinical results can teach about Alzheimer’s disease 2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons these events provide. The quest for a treatment to slow the progression of Alzheimer’s disease has endured decades of disappointments. The most common treatment strategy — clearing up harmful deposits, or “plaques,” […] November 23, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Study shows enhanced drug delivery to the brain In a study recently published in the journal Nature Biomedical Engineering, Japanese researchers used a method called “lasso-grafting” to design therapeutics with enhanced longevity and brain penetration. Cell growth and repair are stimulated by biomolecules known as cytokines and growth factors. Unfortunately, delivering adequate concentrations of these molecules to the brain for treating neurological conditions […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 10 Oct 2022 Positive data indicates likely therapeutic effect of Alzheimer’s drug Positive phase 2a clinical data from an Alzheimer’s disease (AD) biomarker study, has been announced today (October 10). Actinogen Medical Limited shared the news that its study validates its planned program for Xanamem, a potential drug for the disease. The biomarker study was conducted in 72 patients with available blood biomarker samples from the prior […] October 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2022 Japanese scientists find way to detect characteristic of Alzheimer’s disease from blood samples Researchers from Hokkaido University in Japan and Toppan have developed a method to detect build-up of amyloid β in the brain, a characteristic of Alzheimer’s disease, from biomarkers in blood samples. Alzheimer’s disease is a neurodegenerative disease, characterized by a gradual loss of neurons and synapses in the brain. One of the primary causes of […] October 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Human cells can now help scientists accelerate cure for neurodegenerative diseases Cell products providing a scalable source of human cells can now help scientists study neurogenerative diseases in human context. UK-based, cell-coding company, bit.bio announced the expansion to its portfolio today (September 29) with disease model, ioGlutamatergic Neurons TDP-43 and early access to its ioMicroaglia cell product. Despite research efforts and funding, bit.bio says the development […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022 Positive results from Eisai and Biogen Alzheimer’s trial Eisai Co., Ltd. and Biogen Inc. have announced positive topline results from Eisai’s large global phase 3 confirmatory Clarity AD clinical trial of lecanemab to treat mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. Lecanemab is an […] September 29, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email